Alvimopan for post-operative ileus: What we should know?

Area of Science:

• Pharmacology
• Gastroenterology
• Surgical Recovery

Background:

• Alvimopan is a US-FDA approved peripherally acting mu-opioid receptor antagonist.
• It is known to accelerate intestinal motility and decrease the duration of post-operative ileus when administered pre-operatively.

Purpose of the Study:

• To evaluate the practical and economic barriers to the regular clinical use of alvimopan.

Main Methods:

• Review of drug procurement, storage, and dispensing logistics.
• Analysis of the cost-effectiveness of alvimopan for a standard 15-dose course.

Main Results:

• The logistical complexities of handling alvimopan present significant challenges.
• The cost associated with the FDA-approved 15-dose regimen is a major impediment to its routine application.

Conclusions:

• Despite its demonstrated efficacy in enhancing post-operative recovery, the practical and financial burdens associated with alvimopan restrict its widespread adoption.
• Alternative strategies or cost-reduction measures may be necessary to facilitate broader access to this therapeutic agent.